Romosozumab (Evenity): The Bone Drug That Builds and Blocks at the Same Time

Most osteoporosis drugs do one thing: they slow the cells that break bone down. Romosozumab is the exception that does both jobs at once, and that dual action is why it produces the largest density gains of any available treatment — and why it is capped at a single year.

How it works, and why that is unusual

Bone is constantly demolished and rebuilt. Bisphosphonates and denosumab work on the demolition side, slowing osteoclasts. Teriparatide and abaloparatide work on the construction side, stimulating osteoblasts. Romosozumab blocks sclerostin, a protein made by bone cells that normally puts a brake on bone formation. Removing that brake increases building — and, through a linked pathway, also reduces breakdown.

The effect is front-loaded and temporary. Bone formation markers rise sharply in the first months and drift back toward baseline by month twelve, which is the pharmacological reason the course stops there rather than an arbitrary limit.

What the trials showed

FRAME

In postmenopausal women with osteoporosis, twelve months of romosozumab reduced new vertebral fractures by 73% compared with placebo. Spine bone density rose by around 13% and hip density by around 6% — figures well beyond what antiresorptive drugs achieve in the same period.

ARCH

The more clinically useful comparison. In women with osteoporosis and a previous fracture, twelve months of romosozumab followed by alendronate was compared with alendronate throughout. At 24 months, new vertebral fractures were 48% lower and hip fractures 38% lower in the romosozumab arm. This trial is also where the cardiovascular signal appeared.

The boxed warning

In ARCH, serious cardiovascular events — heart attack, stroke and cardiovascular death — occurred more often in the romosozumab group than in the alendronate group during the first year. The absolute numbers were small, and the FRAME trial against placebo did not show the same imbalance, which leaves genuine uncertainty about the mechanism. The FDA nonetheless required a boxed warning.

The practical rule that follows from it: romosozumab is not used in anyone who has had a heart attack or stroke within the previous twelve months, and cardiovascular risk is weighed explicitly before starting. For a woman at high fracture risk and low cardiovascular risk, the calculus usually favours treatment; for the reverse, it usually does not.

Who it is for

It is approved for postmenopausal women at high risk of fracture, which in practice means a previous fragility fracture, multiple risk factors, or failure of or intolerance to other osteoporosis treatments. It is not a first-line drug for someone with osteopenia and no fracture — the risk-factor picture has to justify it.

Because it builds bone, it is generally used before an antiresorptive rather than after. Starting romosozumab in someone already on long-term bisphosphonates produces a smaller response, since those drugs have already suppressed the remodelling it acts on.

What has to follow it

This is the part most often missed. Bone gained during the twelve months is not permanent. Without a follow-on antiresorptive — a bisphosphonate or denosumab started promptly — density falls back toward baseline within about a year. The sequence is the treatment; the injection alone is half of it.

The same logic governs stopping any osteoporosis drug, and it is most urgent with denosumab, where an unplanned gap causes rapid loss and rebound vertebral fractures.

Practical details

How it is given

Two subcutaneous injections at one sitting, once a month, for twelve months. It is usually administered in a clinic. Missing a dose means taking it as soon as possible and resetting the monthly schedule from there.

Common side effects

Joint pain and headache are the most frequently reported. Injection-site reactions are common and mild. Low calcium can occur, so calcium and vitamin D status is corrected before starting and maintained throughout.

Rare but important

Osteonecrosis of the jaw and atypical femoral fracture have both been reported, as with other potent bone drugs. Both are rare. Dental work is ideally completed before starting, and new thigh or groin pain during treatment is reported rather than waited out.

How it compares with the alternatives

Our side-by-side of osteoporosis medications covers the full set, and denosumab has its own guide.

What the first year actually looks like

Knowing the schedule in advance removes most of the friction, because this is a drug where missed appointments cost real bone.

Before the first dose

Calcium and vitamin D status is checked and corrected — starting with low calcium risks pushing it lower. Kidney function is reviewed. Dental work that is pending gets completed, because the small risk of jaw osteonecrosis is concentrated around invasive dental procedures during treatment. Cardiovascular history is taken seriously here rather than as a formality: a heart attack or stroke in the previous twelve months rules the drug out.

Months one to twelve

Two injections at each monthly visit. Bone turnover markers, if your clinic uses them, rise early and drift back down — that pattern is expected and is not a sign of failure. Density is not usually re-scanned mid-course, because twelve months is too short an interval for a DEXA to say anything reliable.

The handover

The follow-on antiresorptive should be arranged before the last injection, not after it. A gap of a few months between finishing romosozumab and starting a bisphosphonate or denosumab wastes part of what the year bought. If denosumab is the follow-on, its own rule then applies permanently: it cannot simply be stopped later without a replacement.

After treatment

A repeat DEXA is typically done one to two years after starting, on the same scanner as the baseline — densities are not comparable between machines, and switching scanners is a common reason a result looks alarming when nothing has changed.

Cost, coverage and access

Romosozumab is a specialty biologic administered in a clinic, which changes how it is billed. In the United States it is frequently covered under the medical benefit rather than the pharmacy benefit, because a healthcare professional administers it — that distinction decides which deductible applies and often whether prior authorization is needed. Insurers commonly require documentation of high fracture risk and, in many cases, evidence that a bisphosphonate was tried, was not tolerated, or was inappropriate.

The manufacturer runs a patient assistance programme. Because the course is finite, the total cost is bounded in a way that ongoing treatments are not — twelve months rather than an indefinite commitment. Our guide to estimating cost and coverage covers how to read your own plan's rules.

Questions worth asking before you start

• What is my ten-year fracture risk, and what does it need to be to justify this? A number gives the decision a shape. The fracture risk check covers the factors that feed into it.
• What is my cardiovascular risk? The boxed warning makes this an explicit part of the calculation rather than background information.
• What drug follows, and is it arranged? If the answer is vague, the plan is incomplete.
• Have I had bisphosphonates before? Prior long-term antiresorptive use blunts the response, and that changes what to expect.
• Is any dental work outstanding? Better completed before starting than deferred through the year.

Why sequence matters more than choice of drug

The most consequential finding in modern osteoporosis treatment is not which drug is strongest but which order they are given in. Starting with a bone-building drug and following with an antiresorptive produces larger and better-held gains than the reverse. Giving romosozumab to someone already suppressed by years of alendronate yields a smaller response, because the remodelling it acts on has already been slowed.

That is why a high-risk treatment plan is usually described as a sequence rather than a prescription — and why the question what comes after deserves as much attention as the injection itself.